Therapeutic Applications of Bilirubin and Biliverdin in Transplantation
Authors:
- 1 December 2007
- journal article
- research article
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 9 (12) , 2175-2186
Abstract
Bilirubin is the end product of heme catabolism by heme oxygenases. The inducible form of these enzymes is heme oxygenase-1 (HO-1), which is the rate-limiting enzyme that can degrade heme into equimolar quantities of carbon monoxide (CO), biliverdin, and free iron. Biliverdin is very rapidly converted to bilirubin by the enzyme biliverdin reductase, and free iron upregulates the expression of ferritin. HO-1 is a ubiquitous stress protein and is induced in many cell types by various stimuli. Induced HO-1 exerts antiinflammatory effects and modulates apoptosis. Expression of HO-1 in vivo suppresses the inflammatory responses in endotoxic shock, hyperoxia, acute pleurisy, and organ transplantation, as well as ischemia–reperfusion injury, and thereby provides salutary effects in these conditions. Accumulating evidence indicates that biliverdin/bilirubin can mediate the protective effects of HO-1 in many disease models, such as IRI and organ transplantation, via its antiinflammatory, antiapoptotic, antiproliferative, and antioxidant properties, as well as its effects on the immune response. This review attempts to summarize these protective roles as well as the molecular mechanisms by which biliverdin/bilirubin benefit IRI and solid-organ transplantation, including chronic rejection, and islet transplantation.Keywords
This publication has 86 references indexed in Scilit:
- Heme Oxygenase-1 and Transplantation ToleranceHuman Immunology, 2006
- Islet Cell TransplantationCurrent Molecular Medicine, 2006
- New Cellular and Molecular Immune Pathways in Ischemia/Reperfusion InjuryAmerican Journal of Transplantation, 2006
- Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidneyAmerican Journal of Physiology-Renal Physiology, 2005
- Neointimal smooth muscle cells in human cardiac allograft coronary artery vasculopathy are of donor originThe Journal of Heart and Lung Transplantation, 2004
- Systemic Rather Than Local Heme Oxygenase-1 Overexpression Improves Cardiac Allograft Outcomes in a New Transgenic MouseThe Journal of Immunology, 2003
- Gene Transfer-Induced Local Heme Oxygenase-1 Overexpression Protects Rat Kidney Transplants From Ischemia/Reperfusion InjuryJournal of the American Society of Nephrology, 2003
- Biliverdin reductase: A major physiologic cytoprotectantProceedings of the National Academy of Sciences, 2002
- Ischemia/Reperfusion InjuryJournal of Surgical Research, 2002
- Balloon Injury Does Not Induce Heme Oxygenase-1 Expression, but Administration of Hemin Inhibits Neointimal Formation in Balloon-Injured Rat Carotid ArteryBiochemical and Biophysical Research Communications, 1999